CTOs on the Move

SQZ Biotech

www.sqzbiotech.com

 
SQZ Biotech is a unique cell therapy company, utilizing the proprietary CellSqueeze® platform to develop a new generation of cell therapies. SQZ currently focuses on the development of novel treatments that leverage targeted immune modulation to impact oncology and autoimmune diseases.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

SQZ Biotech raised $72M on 08/08/2018
SQZ Biotech raised $71.2M on 12/06/2019
SQZ Biotech raised $60M on 02/12/2021

Similar Companies

Somatic Therapies

Somatic Therapies is a Grand Junction, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zalicus

Zalicus is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sinclair Research Center Inc

Sinclair Research Center Inc is a Columbia, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta`s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company`s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please visit our website ( DesCAARTes™ Phase 1 Trial ). The Company`s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.

Redwood Toxicology Laboratory

Redwood Toxicology Laboratory is a Santa Rosa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.